- Home
- OMCL vs SANA Comparison
OMCL vs SANA Comparison
Compare OMCL & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | SANA |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2001 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OMCL | SANA |
|---|---|---|
| Price | $43.26 | $5.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $43.00 | $7.83 |
| AVG Volume (30 Days) | 511.1K | ★ 5.2M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $1,177,740,000.00 | N/A |
| Revenue This Year | $8.61 | N/A |
| Revenue Next Year | $3.97 | N/A |
| P/E Ratio | $103.10 | ★ N/A |
| Revenue Growth | ★ 10.67 | N/A |
| 52 Week Low | $22.66 | $1.26 |
| 52 Week High | $47.69 | $7.30 |
Technical Indicators
Market Signals| Indicator | OMCL | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 70.82 | 59.18 |
| Support Level | $39.18 | $4.25 |
| Resistance Level | $45.36 | $5.43 |
| Average True Range (ATR) | 1.95 | 0.51 |
| MACD | 0.41 | 0.12 |
| Stochastic Oscillator | 80.11 | 78.04 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.